Deltasone (prednisone) is a corticosteroid. It prevents the release of substances that cause inflammation and also suppresses the immune system. The therapy is used to treat many conditions including allergic reactions, breathing difficulties, occasional symptoms of certain cancers, and relapse management in multiple sclerosis (MS).

Corticosteroids works in MS relapse management by closing the damaged blood-brain barrier and reducing inflammation in the central nervous system.

MS patients generally take a three- to five-day treatment of high dose intravenous corticosteroid followed by a gradual dose reduction via an oral corticosteroid (may last from 10 days to five or six weeks). Prednisone is usually the choice for this oral tapering off.

It may also be used orally if the corticosteroid for intravenous treatment is not desired or is contraindicated.

Prednisone should not be taken if a fungal infection is present. Because it weakens the immune system, people taking prednisone shouldn’t be around others who are sick or who have infections.

Some common side effects associated with prednisone include insomnia, mood changes, increased appetite, gradual weight gain, acne, increased sweating, skin problems, difficulties with healing wounds, headache, nausea and gastric disorders, and changes in the shape or location of body fat.

Other prednisone brands are Rayos, Sterapred, Sterapred DS, and Prednicot.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

  1. https://www.drugs.com/prednisone.html
  2. https://medlineplus.gov/druginfo/meds/a601102.html#brand-name-1
  3. http://www.nationalmssociety.org/Treating-MS/Medications/Deltasone
  4. https://www.drugs.com/imprints/deltasone-10-206.html

Immunoadsorption May Be Superior to Plasma Exchange in Treating Steroid-resistant Relapses in MS

A blood-cleansing process known as immunoadsorption appears to be superior to plasma exchange in treating relapses that don’t respond to conventional steroid therapy in people with multiple sclerosis (MS) or clinically isolated syndrome (CIS), a study reports. These findings were reported in “Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple […]

Acthar Gel Quite Effective at Resolving Relapses as Alternative to Corticosteroids, Study Reports

Acthar Gel is more effective for treating flares in multiple sclerosis than other alternatives, including intravenous immunoglobulin or plasmapheresis, a claims-based study from Mallinckrodt Pharmaceuticals reports.

The study “Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population” was published in the journal Neurology and Therapy.

Acthar Gel, developed and marketed by Mallinckrodt Pharmaceuticals, is approved by the U.S. Food and Drug Administration for 19 different indications, including the treatment of acute MS flare-ups in adults who have frequent and recurring relapses.

The compound consists of a gel preparation of adrenocorticotropic hormone, which is injected under the skin or into the muscle. It works by enhancing the production of steroids in the body to reduce inflammation and more rapidly resolve a flare.

Acthar Gel is often used as a treatment alternative (or second-line) in patients who cannot tolerate the side effects of, or have responded poorly to, high-dose corticosteroids (the standard treatment).

Clinical trials have demonstrated that Acthar Gel speeds patients’ recovery from a MS relapse compared to placebo, but no study has shown that it changes the disease’s natural course.

This newly published retrospective study, conducted by Mallinckrodt researchers, evaluated the rate of MS relapses, frequency of treatments used, and their effectiveness (relapse resolution rates) in patients using standard corticosteroid therapy or other alternatives, including Acthar Gel, intravenous immunoglobulin, and plasmapheresis.

Researchers reviewed data covering 9,574 adults with MS flares between 2008 and 2015, using administrative claims data from the insurance company Humana. A total of 25,162 relapse episodes were identified. The mean follow-up time per patient was 2.7 years.

The majority of patients had less than two flares a year, while 26% experienced two or more acute attacks annually. Over the study period, about one third (36.9%) did not recover from one or more flares and required alternative relapse treatments.

Corticosteroids were the first treatment used in 90.4% of the initial relapses — 51.8% with oral corticosteroids, and 38.6% with injections of methylprednisolone (sold as Solu-Medrol). Alternatives used included intravenous immunoglobulin (6.0% of relapses), Acthar Gel (2.2%), and plasmapheresis (1.5%).

The proportion of patients achieving relapse resolution with their first treatment varied considerably among these medications. Treatment was considered effective if no subsequent attacks followed a relapse.

Oral corticosteroids led to a successful relapse resolution in 90.5% of patients (5,710 people), which agrees with prior studies and further supports these therapies being “generally effective,” the researchers wrote. In comparison, methylprednisolone was less effective, treating less than half of the cases (47.8%; 3425 patients).

Noticeably, the study showed that Acthar Gel was the most effective treatment alternative to corticosteroids, resolving relapses in 96.9% of the cases, compared to a lower rate of resolutions for intravenous immunoglobulin, and plasmapheresis.

These data demonstrate Acthar Gel’s “effectiveness in appropriate patients,” the researchers wrote. More studies regarding the treatment’s safety, however, are needed.

“The management of MS relapse is an ongoing challenge, in particular for those patients who need additional treatment options after first-line agents such as corticosteroids,” George Wan, PhD, Mallinckrodt’s vice president and global head of health economics and outcomes research, said in a press release.

“We are committed to working toward a better understanding of the potential clinical and health economic outcomes associated with Acthar Gel and other late-line treatments for MS relapse to help guide clinical practice,” Wan added. “In addition, we look forward to the results of Mallinckrodt’s ongoing, randomized, double-blind, placebo-controlled OPTIONS study, which we anticipate will provide data on some of the more difficult-to-treat MS patients in the future.”

Mallinckrodt’s OPTIONS study is evaluating the efficacy and safety of multiple doses of Acthar Gel in adults with relapsing-remitting MS (RRMS) who have not responded to high-dose steroids. The trial is recruiting patients at 30 sites across the U.S.; contact and location information is available using this link.

Interferons Superior to Glatiramer Acetate, and Tysabri More Effective than Gilenya for RRMS, Real-world Study Finds

Interferon therapy (brand names Avonex, Betaseron, and others) is more effective than glatiramer acetate (sold as Copaxone, Glatopa and other generics) for reducing relapses and disease activity, and delaying disability worsening, in patients with relapsing-remitting multiple sclerosis (RRMS), a large real-world study found. The study also showed that, in clinical practice, second-line treatment with Tysabri […]

Long-term Gilenya Treatment Safe and Effective for Relapsing MS Patients, Phase 3 Trial Shows

Long-term treatment with Gilenya (fingolimod) in patients with relapsing forms of multiple sclerosis (MS) is safe and effective, results from a Phase 3 trial show. Trial findings were reported in the study, “Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results,” published in the journal Therapeutic Advances in Neurological Disorders. MS is […]

Acthar Gel Eases MS Flare-up Symptoms After Two Months of Treatment, Observational Study Shows

Acthar Gel (repository corticotropin injection) eased flare-up symptoms in patients with multiple sclerosis (MS) experiencing relapses, top-line data from an observational registry study shows. Acthar Gel, a medication developed and marketed by Mallinckrodt Pharmaceuticals, is a compound that enhances the production of steroids in the body. It has been approved by the U.S. Food and Drug […]

#ECTRIMS2019 — Ponesimod Superior to Aubagio in Relapsing MS, OPTIMUM Trial Shows

Actelion‘s ponesimod, an investigational oral treatment, is superior to Sanofi‘s Aubagio (teriflunomide) in lessening the frequency of relapses and easing fatigue symptoms in adults with active, relapsing multiple sclerosis (MS), results of the OPTIMUM trial show. These data will lay the ground for submissions in the United States and Europe seeking approval of ponesimod as […]

#ECTRIMS2019 – Acthar Gel Seen as Cost-effective Late-line Treatment Option for MS Relapses

Late-line use of H.P. Acthar Gel to treat relapses in adults with multiple sclerosis (MS) is linked with lower costs than other therapies used after an initial poor response, including plasmapheresis and intravenous immunoglobulin, according to an analysis by Mallinckrodt Pharmaceuticals, the treatment’s marketer. George Wan, PhD, Mallinckrodt’s vice president and global head of health economics and outcomes […]

#ECTRIMS2019 – Tysabri During Pregnancy and After Delivery Seems Safe, Reduces Relapse Risk, Study Finds

Continuing Tysabri (natalizumab) treatment up to week 28 of pregnancy, and restarting soon after birth, reduces the risk of relapses in women with multiple sclerosis and appears to be safe for the mother and the baby, new research suggests. Doriana Landi, MD, PhD, from Italy’s University of Rome Tor Vergata, presented the findings at the […]

#ECTRIMS2019 — Ofatumumab Superior to Aubagio in Lowering Relapse Rates and Lesions, Data Show

Monthly under-the-skin injections of ofatumumab are superior to Aubagio (teriflunomide) to treat relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), leading to over 50% reduction in relapse rates, and more than a 90% reduction in active brain lesions, compared with Aubagio, results from ASCLEPIOS I and II trials show. Ofatumumab may represent a highly […]